Older Adults Face Four Vaccine Decisions This Fall While the Federal Schedule Still Carries a 2025 Date - Medical Daily

Latest News About Flu vaccine collaboration between Osivax and GC Biopharma advances

Osivax and GC Biopharma unveiled a major partnership focused on developing a more advanced influenza vaccine. The vaccine will combine OVX836 and GC FLU. Osivax secured rights to advance a combo shot.

Older adults face four vaccine decisions this fall, while the national vaccine schedule continues to carry a 2025 date. Flu and pneumonia deaths have declined for 25 years, but one American age group recorded a rise.

Sources & References